Overview

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Grünenthal GmbH
Tris Pharma, Inc.
Treatments:
Analgesics